GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s share price gapped up before the market opened on Wednesday . The stock had previously closed at $85.22, but opened at $88.77. GeneDx shares last traded at $90.84, with a volume of 211,273 shares traded.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on WGS shares. Piper Sandler began coverage on shares of GeneDx in a report on Wednesday. They set an "overweight" rating and a $110.00 price objective on the stock. Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. TD Securities dropped their target price on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a research report on Friday, May 9th. Finally, Guggenheim restated a "buy" rating and set a $115.00 target price (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $92.33.
Check Out Our Latest Analysis on WGS
GeneDx Trading Down 3.8%
The firm has a 50-day moving average price of $73.18 and a 200-day moving average price of $82.65. The stock has a market cap of $2.39 billion, a PE ratio of -59.33 and a beta of 2.01. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.07 and a current ratio of 3.25.
GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17. GeneDx had a negative net margin of 11.69% and a positive return on equity of 10.17%. The firm had revenue of $87.12 million for the quarter, compared to the consensus estimate of $79.90 million. As a group, equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.
Insider Transactions at GeneDx
In other news, CFO Kevin Feeley sold 1,344 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $91.12, for a total value of $122,465.28. Following the sale, the chief financial officer directly owned 7,425 shares of the company's stock, valued at $676,566. This represents a 15.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Katherine Stueland sold 9,657 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $90.94, for a total transaction of $878,207.58. Following the completion of the transaction, the chief executive officer owned 4,940 shares of the company's stock, valued at approximately $449,243.60. This represents a 66.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,913 shares of company stock valued at $1,314,514 in the last 90 days. Insiders own 29.60% of the company's stock.
Institutional Trading of GeneDx
Institutional investors and hedge funds have recently bought and sold shares of the stock. Sterling Capital Management LLC raised its position in GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after purchasing an additional 316 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in GeneDx during the fourth quarter worth about $35,000. GAMMA Investing LLC boosted its holdings in GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after buying an additional 264 shares in the last quarter. Comerica Bank acquired a new position in GeneDx during the fourth quarter worth about $50,000. Finally, US Bancorp DE raised its position in GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company's stock worth $50,000 after acquiring an additional 548 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Further Reading
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
